# US 2004/0204500 A1 · Preventives/remedies for organ functional disorders and organ dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204500 A1
- Document ID: US20040204500A1
- Status: Published application
- Kind: A1
- Application number: 10/480,707
- Filed: 2003-12-11
- Published: 2004-10-14
- Earliest claimed: 2001-06-28
- Inventors: Yasuo Sugiyama; Tomoyuki Nishimoto; Yoshihiro Kiyota
- Web page: https://patentgrep.com/patent/US20040204500A1

## CPC

- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 267/14: condensed with one six-membered ring
- C07D 281/10: condensed with one six-membered ring
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.

## Claims

### Claim 1

An agent for preventing or treating organ functional disorders comprising a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof;

### Claim 2 (depends on 1)

The agent according to claim 1 for preventing or treating ischemic organ functional disorders;

### Claim 3

An agent for preventing or treating organ dysfunction comprising a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof;

### Claim 4 (depends on 3)

The agent according to claim 3 for preventing or treating ischemic organ dysfunction;

### Claim 5 (depends on 1, 2, 3, 4)

The agent according to any one of claims 1 to 4, wherein the organ is heart, brain, pancreas, kidneys or nervous tissue;

### Claim 6 (depends on 1, 2, 3, 4)

The agent according to any one of claims 1 to 4, wherein the organ is heart;

### Claim 7 (depends on 1, 2, 3, 4)

The agent according to any one of claims 1 to 4, wherein the organ is brain;

### Claim 8 (depends on 1, 2, 3, 4)

The agent according to any one of claims 1 to 4, wherein the compound having an effect of increasing ubiquinone is a compound having a squalene synthase inhibitory effect;

### Claim 9 (depends on 8)

The agent according to claim 8, wherein the compound having a squalene synthase inhibitory effect is a compound of the formula:
26
wherein
R1 is a hydrogen or an optionally substituted hydrocarbon group,
R2 and R3 are, same or different, each a hydrogen, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group,
X′ is a substituent constituted by an optionally esterified carboxyl group, an optionally substituted carbamoyl group, an optionally substituted hydroxy group, an optionally substituted amino group or an optionally substituted heterocyclic residue having a hydrogen atom that may be deprotonated,
ring A is an optionally substituted benzene ring or an optionally substituted heterocycle,
ring J′ is a 7- or 8-membered heterocycle comprising three or less heteroatom(s) as the ring-constituting atoms, wherein ring J′ may have additional substituents besides R1, R2, R3 and X,
or a salt thereof;

### Claim 10 (depends on 8)

The agent according to claim 8, wherein the compound having a squalene synthase inhibitory effect is a compound of the formula:
27
wherein
R1 is a hydrogen or an optionally substituted hydrocarbon group,
R2 and R3 are, same or different, each a hydrogen, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group,
X1 is a bond or a divalent atom chain,
Y is an optionally esterified carboxyl group, an optionally substituted carbamoyl group, an optionally substituted hydroxy group, an optionally substituted amino group or an optionally substituted heterocyclic residue having a hydrogen atom that may be deprotonated, and
ring B is an optionally substituted benzene ring
or a salt thereof;

### Claim 11 (depends on 8)

The agent according to claim 8, wherein the compound having a squalene synthase inhibitory effect is a compound of the formula:
28
wherein
Rb is a lower alkyl group optionally substituted with an optionally substituted hydroxy group,
Xb is an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a hydrogen atom that may be deprotonated,
R1b a lower alkyl group, and
W is a halogen atom,
or a salt thereof;

### Claim 12 (depends on 11)

The agent according to claim 11, wherein Rb is a C1-6 alkyl optionally having 1 to 3 substituent(s) selected from hydroxy, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy;

### Claim 13 (depends on 11)

The agent according to claim 11, wherein R1b is methyl;

### Claim 14 (depends on 11)

The agent according to claim 11, wherein W is a chlorine atom;

### Claim 15 (depends on 11)

The agent according to claim 11, wherein Xb is a group of the formula:
29
wherein
R2b and R3b are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an acyl group, or
R2b and R3b may formtogether with the adjacent nitrogen atom an optionally substituted 5- or 6-membered nitrogen-containing heterocycle which may contain 1 to 3 heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom as the ring-constituting atoms;

### Claim 16 (depends on 11)

The agent according to claim 11, wherein Xb is a group of the formula:
30
wherein
R″ is a hydrogen atom or a C1-4 alkyl;

### Claim 17 (depends on 8)

The agent according to claim 8, wherein the compound having a squalene synthase inhibiting effect is a compound of the formula:
31
wherein
R1c is a 1-carboxyethyl group optionally having substituent(s), a carboxy-C3-6 straight chain alkyl group optionally having substituent(s), a C3-6 straight chain alkyl-sulfonyl group optionally having substituent(s), a (carboxy-C5-7 cycloalkyl)-C1-3 alkyl. group optionally having substituent(s), or a group of the formula —X1c—X2c—Ar—X3c—X4c—COOH COOH (wherein X1c and X4c are each a bond or a C1-4 alkylene group optionally having substituent(s), X2c and X3c are each a bond, —O— or —S—, Ar is a divalent aromatic ring group optionally having substituent(s), provided that when X1c is a bond, X2c is a bond, and when X4c is a bond, X3c is a bond),
R2c is a C3-6 alkyl group optionally substituted with an alkanoyloxy group and/or a hydroxy group,
R3c is a lower alkyl group, and
W is a halogen atom,
provided that when R1c is a 1-carboxyethyl group having substituent(s), a carboxy-C3-6 linear alkyl group having substituent(s), 4-carboxycyclohexylmethyl group or 4-carboxymethylphenyl group, R2c is a C3-6 alkyl group having an alkanoyloxy group and/or a hydroxy group,
or a salt thereof;

### Claim 18 (depends on 17)

The agent according to claim 17, wherein R2c is a C3-6 alkyl group optionally having 1 to 3 substituent(s) selected from hydroxy, acetoxy, propionyloxy, t-butoxycarbonyloxy and palmitoyloxy;

### Claim 19 (depends on 17)

The agent according to claim 17, wherein R3c is a methyl group;

### Claim 20 (depends on 17)

The agent according to claim 17, wherein W is chlorine atom;

### Claim 21 (depends on 17)

The agent according to claim 17, wherein the 3-position has R-configuration and the 5-position has S-configuration;

### Claim 22 (depends on 8)

The agent according to claim 8, wherein the compound having a squalene synthase inhibitory effect is
(3R,5S)-N-propanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(2R)-2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminopropionic acid,
3-[3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminophenyl]propionic acid,
4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminobutanoic acid,
trans-4-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminomethyl-1-cyclohexanecarboxylic acid,
trans-4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminomethyl-1-cyclohexanecarboxylic acid,
3-[3-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluorophenyl]propionic acid,
3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methylphenyl]propionic acid,
3-[3-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methylphenyl]propionic acid,
3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminomethyl]phenyl]propionic acid,
3-[3-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminomethyl]phenyl]propionic acid,
3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxyphenyl]propionic acid,
2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]furan-3-carboxylic acid,
3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazen-3-yl]acetyl]amino]-4-fluorophenyl]propionic acid,
3-[4-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminophenyl]propionic acid,
N-methanesulfonyl-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetamide,
N-methanesulfonyl-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetamide,
N-[2-(pyrrodin-1-yl)ethyl]-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetamide,
N-[2-(pyrrodin-1-yl)ethyl]-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetamide,
N-methanesulfonyl-[(3R,5S)-1-[3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetamide,
N-methanesulfonyl-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetamide,
N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid,
N-[[(3R,5S)-1-(3-hydroxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid,
N-[[(3R,5S)-1-(2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid,
N-[[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid,
N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid ethyl ester,
N-[[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid ethyl ester,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepin-2-one,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepin-2-one,
(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepin-2-one,
(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepin-2-one,
N-[2-(pyrrodin-1-yl)ethyl]-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetamide,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid,
(3R,5S)-7-chloro-5-(2,4-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid,
(3R,5S)-7-chloro-5-(4-ethoxy-2-methoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid,
2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]furan-3-carboxylic acid,
4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxyphenyl]butanoic acid,
5-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxyphenyl]pentanoic acid,
5-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluorophenyl]pentanoic acid,
2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]furan-3-carboxylic acid,
3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazen-3-yl]acetyl]amino]-4-fluorophenyl]propionic acid,
3-[3-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminophenyl]propionic acid,
or a pharmaceutically acceptable salt thereof;

### Claim 23

An agent for increasing ubiquinone, comprising the compound of the formula (I) or a salt thereof or a prodrug thereof;

### Claim 24

An agent for increasing ubiquinone, comprising the compound of the formula (Ia) or a salt thereof or a prodrug thereof;

### Claim 25

An agent for increasing ubiquinone, comprising the compound of the formula (Ib) or a salt thereof or a prodrug thereof;

### Claim 26

An agent for increasing ubiquinone, comprising the compound of the formula (Ic) or a salt thereof or a prodrug thereof;

### Claim 27

An agent for preventing or treating obesity and deuteropathy thereof, comprising a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof;

### Claim 28 (depends on 23, 24, 25, 26)

The agent according to any one of claims 23 to 26, which is an agent for preventing or treating obesity and deuteropathy thereof;

### Claim 29

An agent for suppressing progress of cerebral infarction, comprising a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof;

### Claim 30 (depends on 23, 24, 25, 26)

The agent according to any one of claims 23 to 26, which is an agent for suppressing progress of cerebral infarction;

### Claim 31

Use of a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof, for the production of an agent for preventing or treating organ functional disorders, organ dysfunction, or obesity and deuteropathy thereof, or for the production of an agent for suppressing progress of cerebral infarction;

### Claim 32

A method for treating or preventing organ functional disorders, organ dysfunction, or obesity and deuteropathy thereof, or a method for suppressing progress of cerebral infarction, comprising administering an effective amount of a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof to a mammal;

### Claim 33

A method for increasing ubiquinone, comprising administrating an effective amount of a compound of the formula (I) or a salt thereof or a prodrug thereof to a mammal.
